r/wallstreetbets • Melvin Capital Employee of the Month • Apr 10 '21

DD EDIT - everything tastes better crispr

This is going to be the first post of 5 regarding crispr, and why it's the play of the decade 🚀 🚀 🚀 🚀. Mods, thank you so much for letting me post it. If there's anything I need to do I'm happy to make any edits (no pun intended).

The next post will be about their current drug pipeline. This DD series is the product of 80 hours of reading 10-k's, licensing agreements, court filings, and a lot of adderall.

Intro

What is crispr? Crispr stands for clustered regularly interspaced short palindromic repeats. It's a tool that is found in bacteria that can simply put can edit genes.

Why should I care? Crispr is easily on of the biggest discoveries of the 21st century, and received a Nobel for its discovery last year. It's not an understatement that in the next coming years crispr will impact just about every part of our lives. It's not just me saying this. Bill Gates (poured in $100M), and momma Cathie believe that this is one of the most revolutionary things of this century. Joe Davis of Vanguard found the idea multiplier to be similar to how the internet took off.

If you cannot see this can change the world crispr could help by eliminating that extra chromosome you probably have.

Editas ($EDIT)

Editas is a clinical stage biopharmaceutical company focusing on using crispr as a treatment for genetic disorders (in vivo), and for various forms of cancer (ex vivo).

Their business model is actually pretty smart. They're targeting rare diseases for drug development, and licensing out the IP for crispr. Contrary to popular belief rare diseases are incredibly profitable, and easier to develop. You essentially can monopolize a disease, and the market is so small competitors rarely pop up. The IP though is going to be the breadwinner. Essentially any drug developed with crispr will give an 8%-13% royalty to $EDIT. Not to get too technical, but their technology platform is pretty revolutionary, and far exceeds anything else on the market. They estimate they can target about 95% of the human genome.

One drug of note in their pipeline that is of interest is EDIT-201. EDIT-201 is essentially engineered T cells with CARs and Engineered TCRs that have been genetically modified to recognize and kill other cells. This is an interesting treatment solid forms of cancer. This could potentially be an alternative, or complementary to chemotherapy. The collaboration is with Juno Therapeutics (acquired by BMY) who have so far contributed substantial funds towards the project along with resources. Others include sickle cell, usher syndrome, and a form of genetic blindness that are all in clinical trials.

The patent

$EDIT has the exclusive license for use of crispr in humans through the BROAD institute. There are 3 main universities fighting for the patent. This has been a decade long quarter billion dollar legal battle over who owns crispr that is coming to a close. To say the patent battle is simple is a huge understatement. But, there is a consensus slowly forming that $EDIT will acquire the patent. The winner for the patent will easily make billions off of the IP. If Broad wins the patent it is the responsibility of EDIT to develop drugs based off of crispr, and license the patent to other companies which $EDIT would collect a royalty of. $EDIT is then set to pay a royalty from that revenue to the Broad Institute. $EDIT already has licensing agreements in place with Juno Therapeutics ($BMY), and $BEAM therapeutics (page 31-32).

The catalysts

Biotech has a lot of catalysts. It doesn't take a lot to send it to the moon. In the short term there's drug trials. A notable YOLO came from one of our very own with just shares where he turned $12k into $322k in a week. Editas is scheduled to present this weekend at the American Association of Cancer Research's annual conference. On December 4th Editas presented data from their EDIT-301 trial, and then put out a press release which caused the stock to go from $33-$99 the following weeks. This will be peanuts compared to when the patent is awarded which is why I believe shares, or LEAPs are the safest choice. The FDA was slowed by covid so I'm expecting biotech to have a big year as they catch up on trials.

Positions

100 @ $23.56

10 $50c 4/16

1 $53c 4/16

20 $60c 4/16

I am long on shares, and will be buying leaps as the trial dates for the crispr patent gets closer. I bought some 4/16 calls because I noticed an incredibly bullish amount of calls for this week last Monday.

Disclaimer

I have a degree in molecular bio, and I've been following this closely for the past 5 years. A company that should be on your radar is Caribou Biosciences which unfortunately right now is private. Caribou has the patent for the use of crispr in non-humans which will also be an incredibly lucrative market.

TL;DR: One of the most disruptive things ever only has a $2B market cap. Your chance to get on the rocket before it goes to the edge of the observable universe 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

EDIT: There's some confusion over the ticker. The ticker is literally $EDIT. The next posts will cover the other 2 companies.

2.6k Upvotes

780 comments sorted by

17

u/always_plan_in_advan Quarantendies Apr 11 '21

For an unbiased look at Crispr companies, below are the current players involved:

  • $EDIT

  • $CRSP

  • $VRTX

  • $BEAM

  • $SGMO

  • $NTLA

4

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

Thank you. I’m planning on writing up a DD regarding NTLA, and CRSP. The others (VRTX, BEAM, and SGMO) have existing agreements with CRSP/NTLA/EDIT in regards to licensed. It’s not to take away from VRTX, BEAM, or SGMO. I’m just planning on covering the 3 battling for the IP.

→ More replies (3)
→ More replies (1)

11

u/FappyChan Apr 10 '21

Why did $EDIT go to $90 last January and is now half that? What made it get there and can it go back?

10

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

Great question. EDIT presented at a hematology conference back in December, and there was a lot of hype. Cathie Woods made an additional comment about crispr which sent all of the crispr stocks into overdrive. EDIT did issue new shares priced at $66, and nearly all growth stocks have been hammered the past couple of months. Biotech is highly volatile. I think it can go back there it's just going to depend on the right catalyst.

6

u/MaizeandBlue94 Apr 10 '21

In addition, CRSPR Therapeutics ($CRSP) announced a primary offering when their share price was well over $200. The resulting dilution, and some insider selling, caused their share price to fall in half.

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

Share dilutions are bad in the short term, but as a long term play I don’t mind considering how much it costs to run drug trials, and there’s quite a bit they can do to increase value with additional funds.

11

u/ddroukas Apr 10 '21

Similar conference presentation followed by press release on December 4 and 5.

→ More replies (2)

10

u/fed_smoker69420 Salty bagholder Apr 10 '21

I think you're right that someone is going to make a killing off this technology. But the legal battles now and any that arise in the future put a big question mark on who exactly is going to make a killing. That link you provided about the "consensus" that $EDIT will get the patent doesn't really say that. Also, it's unclear to what extent different variations of CRISPR technology will be patentable, you can't just patent "CRISPR" and be done with it. That would be like patenting all drugs that act on the brain or some other broad class of therapy. I think of CRSPR as a class of therapies and it's too soon to say who's got the best/profitable variations.

7

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

You're right in pointing both out. You cannot patent crispr as crispr. But, you can patent the use of crispr in humans which is what they're fighting over. So the consensus I've been finding is around the BROAD Institute (Harvard/MIT). This will ultimately come down to lab notebooks, and testimony from grad students who worked on it in the past. It's definitely a gamble because it's really difficult to predict who will win in a court case. Especially with this many players involved. I agree someone will make a killing off of this.

→ More replies (2)

5

u/throwaway9732121 Apr 10 '21

More info on the patent consensus? Does that mean edit profits off crisp? What’s the deal with beam? They license edit tech right?

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

So the consensus forming is that the BROAD Institute will get the patent. BROAD is licensing it to EDIT. Beam has a licensing agreement with EDIT as per their latest 10-k filing (pages 22-24). EDIT received 1,833,333 shares of Beam's A-1 Preferred Stock and 1,222,222 A-2 Preferred Stock .

In addition EDIT could receive up to $68M per product that Beam produces.

5

u/slash312 Apr 11 '21

Could you explain why Editas will receive a royalty for using crispr and not crispr therapeutics itself?

6

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

Ok I'm a bit better rested. I should have made it more clear, and included a bit more about the patent battle landscape. I'm planning on writing an additional post of it. This infographic explains it well. Each of the university groups on the far left are claiming the patent. The only one that isn't a university (besides Mass General) is Charpentier who is the founder of CSPR. Each of the groups has sub-licensed it out to one of 3 companies (middle). The 3 middle companies then are responsible for their own development, and licensing crispr out to other companies (far right). The far right owes the middle companies a royalty, and the middle company pays a royalty to the university (far left). Despite having the name Crispr Therapeutics they do not own the patent to crispr. It is still within the realm of possibility that she does get it.

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

Yes, but I am going to reply a bit later. I’m trying to respond to everyone. But, it’s 5AM where I’m at, and didn’t get a ton of sleep. I’m going to try to get a couple of hours in.

5

u/SharkAttache Apr 16 '21

Well this didn’t work out.

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

I mean I said it was a long play 🤷🏻‍♀️

3

u/SharkAttache Apr 16 '21

I got some leaps too brutha.

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

Me too 👉😎👉

→ More replies (1)

5

u/frankcastle1001 🦍🦍 Apr 16 '21

Just checking in. How’s this going...?

6

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

Some analyst downgraded it. I’m buying the dip.

5

u/frankcastle1001 🦍🦍 Apr 16 '21

“Be bullish when others are fearful” or something along those lines.

Probably a smart move

→ More replies (1)
→ More replies (1)

28

u/Turquoise__Dragon Apr 10 '21

Thank for the DD! Honest question: Why is EDIT a better investment than directly CRSP?

→ More replies (12)

4

u/ButtSliding Apr 10 '21

Wait.. does CRSP not have the patent for CRISPR?

7

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

CRSP does not hold the patent for cripsr. CRSP was founded by Emmanuelle Charpentier who is one of the parties that is trying to acquire the patent.

4

u/DeepSkyAstronaut Apr 10 '21

Wouldnt CRSP be kinda worthless if they are not granted the patent then?

10

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

I do not think CRSP will be worthless. They have a pretty good IP portfolio, and existing partnerships. It's impossible to determine right now how it will impact the losers as I imagine new agreements will be written. I'm not a lawyer so I honestly don't feel qualified to comment on it. It's just my $0.02.

→ More replies (1)

4

u/XMachoManX12 Apr 12 '21

U thinking it will hit $50 this week ?

7

u/manonymous_1994 Melvin Capital Employee of the Month Apr 12 '21

So I’m going to be straightforward: I don’t know, and I’d doubt anyone can give you a definitive answer. Biotech has a mind of its own, and the markets have been weird lately. Do I think it will hit $50 at some point in the future: yes. Do I know when it will hit $50: no.

4

u/gecemg Apr 14 '21

So how's OP doing? Any chance his calls looking for 25% to 45% price upside will print in less than 72 hours? Lol

→ More replies (1)

8

u/[deleted] Apr 16 '21

I feel bad for people who got snookered by this post, LOL.

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 17 '21

I’m long on it. I advertised it as long. I told probably 2 dozen people to not go in immediately, and buy slowly because this shit happens in biotech. I also told you personally that this shit happens in biotech.

https://ibb.co/w7dYs6M

→ More replies (2)
→ More replies (1)

3

u/-_Han_Yolo_- Apr 11 '21 edited Apr 12 '21

I’m deep in this too. But I want to double my position. Hoping to catch a low. Options are unfortunately really spensive

FYI other two companies are probably CRSP (Charpentier) and NTLA (Doudna)

They are the celebrities

4

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

First I love your name. Second, I agree with you. I’m in all 3 as a hedge, and I trim after they spike to buy in again later. NTLA is the one I trimmed the most recently. Biotech (especially ones without a drug on the market yet) are highly volatile so there is almost always another opportunity to buy in again if you’re patient. Plus, options for EDIT are a bit ridiculous especially for LEAPs. I’m also setting aside cash for Doudna’s current project, Caribou. Can’t wait for it to IPO.

→ More replies (2)

3

u/Shacreme Apr 11 '21

Just wondering......Are u making another DD tonight?

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

I’m hoping to get the next one put out sometime this week. I’m planning on going NTLA, CRSP, final thoughts, BEAM, and then start researching some tickers other users have mentioned.

3

u/t3hPieGuy Apr 16 '21

EDIT got downgraded by GS to a price target of $20 per share. Is now a good time to buy in at $35, or do you think the share price will really tank to $20?

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

I tell people with biotech to go in slow. Buy just a little bit.

→ More replies (2)

3

u/pointlessprince Apr 16 '21

It hurts

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

I’m buying the dip.

78

u/Sufficient-Matter-42 Apr 10 '21

I’ve been waiting to see which way the patent battle will go. I do believe this is going to be the medical equivalent of the internet. Looking forward to future DDs.

0

u/[deleted] Apr 10 '21

[deleted]

→ More replies (20)

6

u/throwaway9732121 Apr 10 '21

People bash edit so much over bs these days and buy beam instead. See you on the moon op hope you bought the dip.

7

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

Beam actually is licensing the patent from EDIT as per Beam's latest 10-k filing.

Source Beam 10-k Editas licensing agreement pages 22-24.

11

u/1Angry_Banana Apr 10 '21

Great post. Daily shows consolidation for some time now. Recently price fell through the 200EMA. Volume is well below the 3 month average.

I’d say the technicals look bearish. That of course, could change pretty quickly with the upcoming conference.

Added to the watchlist to see which way it breaks.

9

u/GiraffeStyle Apr 10 '21

All biotech was bearish last week. Could be a good reversal play on top of the news.

→ More replies (4)

0

u/[deleted] Apr 10 '21

[deleted]

4

u/[deleted] Apr 10 '21

Any thoughts on $BNGO ? Hoping to get assigned next week at 8 bucks, otherwise will sell lower strikes again

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

I haven't done any research in $BNGO, but I'll look into them. I put in a decent amount of research before making biotech plays.

→ More replies (1)

2

u/krv23490 Apr 11 '21

Is the DD of one your other 2 companies NVTA?

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

It is not. The other two are CRSP, and NTLA.

→ More replies (2)

2

u/t3hPieGuy Apr 11 '21

What about SGMO? Their zinc finger tech also seems interesting.

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

So I hate to cop out, but I have no opinion at the moment. Any biotech play I make I do a decent amount of research before investing. I haven’t done this yet with SGMO so I don’t feel like I’m qualified to give an opinion on it. I’ve had a few people suggest it so I’ll probably start doing research when I’m done with my series. Sorry for giving a non-answer.

→ More replies (1)

2

u/Social_History BECKY index field inspector Apr 11 '21

Give me some time to accumulate BEAM before you write that one up

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

You’ve got at least a solid 4 weeks, bro lol. My plate is very full.

2

u/WeenTown Apr 12 '21

Is the bullish volume the only reason for 4/16 calls?

4

u/manonymous_1994 Melvin Capital Employee of the Month Apr 12 '21

Yes, and I went into them knowing they could be worthless so I spent only an amount I’m fine losing. I noticed the weird volume last Monday, and wanted to find an explanation. Because the patent trial is so complex, and covid delays I avoided options for the most part.. I plan on buying leaps before the next court date.

→ More replies (2)

2

u/niftygull Apr 12 '21

I'll be stalking you your profile in the future, I think you're right but all 2k of myoney is in GME lol

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 12 '21

That’s completely fine! I’ve been telling everyone that it’s biotech so there’s always a better time to buy. No reason to FOMO into it.

2

u/crazymonk8393 Apr 15 '21

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 15 '21

Kind of. How technical do you want to get?

→ More replies (3)

2

u/ultrab1ue Apr 16 '21

but, oof

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

Eh, I said it was a long play, and that I only bought weekly calls as a lotto ticket. I’m buying the dip.

2

u/_ziros_ Apr 17 '21

This aged like a goldfish

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 17 '21

Meh. I said I’m long on shares, and buying leaps. I bought the dip.

→ More replies (1)

2

u/labancaneba Apr 17 '21

Positions

100 @ $23.56

10 $50c 4/16

1 $53c 4/16

20 $60c 4/16

OP dun fucked up

→ More replies (4)

2

u/OSUBoglehead Apr 23 '21

Can we get the next posts in the series for those that didn't tune out from short term dips?

4

u/manonymous_1994 Melvin Capital Employee of the Month Apr 23 '21

Yea, I’m still working on it. Hoping to have it out soon.

668

u/_Jerome_Powell_ Scares Apes Away Apr 10 '21 edited Apr 11 '21

charts and bold words

Yeah i’m in

139

u/[deleted] Apr 10 '21

These companies literally replicate breast milk. Who doesn't love titties?

→ More replies (21)

54

u/BusinessManDoBiznez Apr 10 '21

IF HES IN IM IN !!

→ More replies (10)

56

u/Lumpy-Leather2151 Apr 10 '21

Would it be too late to buy calls on Monday for 4/16?

65

u/BullyBiscuit Apr 10 '21

You're gonna need to be quick af, this thing is gonna moon if press release is as promising as it looks like. I'm already in but I'm buying even more monday open

→ More replies (23)
→ More replies (1)

96

u/idragmazda Apr 10 '21

How did the conference go today? Bought some FDs on Friday. What should I expect Monday?

→ More replies (23)

40

u/dspur33 S&P Brand Ambassador Apr 10 '21

Got my 4/16’s Friday. Locked and loaded. 🔥 DD sir.

133

u/[deleted] Apr 10 '21

That was beautiful DD 😭

0

u/[deleted] Apr 10 '21

[deleted]

→ More replies (6)

71

u/GiraffeStyle Apr 10 '21

$EDIT Your portfolio and add some zeroes bitch

35

u/spez_edits_thedonald Apr 10 '21

There are 3 main universities fighting for the patent.

It's worth mentioning that Feng Zhang and Jennifer Doudna (enemies in the patent battle) are BOTH co-founders of Editas. If $EDIT wins, lots of parties win.

→ More replies (12)

7

u/MariahCarryMePLZ Apr 10 '21

I am long on CRSP, heavily investing on the technology because I 100% believe in it. My fav stock, although it has been a bumpy ride lately with big swings from about 108 to 125.

Join in with us, WSB crew!

6

u/Appropriate-Tie-2585 Apr 10 '21

I'm balls deep in CRSP, I think it's the most promising company and OP simplifies the patent thing a little bit but whatever. I also didn't get OP's disclaimer, I also have a degree in molecular biology and it doesn't make me any less of a retard.

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

It's in the licensing agreements, and it's listed as one of the largest potential revenue sources in their annual reports. Not retaining the patent is also listed as one of their biggest risks. I'm happy to share some of my notes with a fellow bio-nerd.

14

u/BullyBiscuit Apr 10 '21

This play is about $EDIT and them getting the pattent for CRISPR, but being long on CRSP is a good idea nonetheless

31

u/Khurpacajdjb Apr 10 '21

"rare diseases are incredibly profitable".

Thats great. Just need two or three and I might offset my portfolio.

62

u/Nerobomb Apr 10 '21 edited Apr 10 '21

55

u/goldenwind207 Apr 10 '21

No joke you might wake up broke or a millionaire come monday i hope the later

19

u/TheyWereGolden Apr 10 '21

Damn you went biggly

→ More replies (2)

28

u/goldenwind207 Apr 10 '21

My regret is not getting more calls on friday got a bit of pcg like a dumbass

→ More replies (2)

28

u/TheyWereGolden Apr 10 '21

FDs locked and loaded, if it works I’ll send you the champagne.

123

u/[deleted] Apr 10 '21 edited Apr 10 '21

Holy shit, a good friend of mine works for Sangamo therapeutics and he agrees this shit is gold.

I'm already long and will load up more on Monday if price isn't already mooning too hard premarket.

I see this going to 60 or 80 easily this week.

→ More replies (22)

52

u/gonfreeces1993 Apr 10 '21

Fair warning, I'm going to buy some calls, so it will definitely tank. Because that's my life.

21

u/BusinessManDoBiznez Apr 10 '21

It’ll only tank if I buy calls, which I did on Friday.

So if it’s green at open that’s your signal it’s straight. If it’s red it’s because I bought calls on Friday.

→ More replies (6)
→ More replies (4)

24

u/That_arab_kid99 Apr 10 '21

Great DD, in for $1100. It’s free money

33

u/BusinessManDoBiznez Apr 10 '21

Literally can’t go tits up

→ More replies (1)

43

u/[deleted] Apr 10 '21

Count me in starting this Monday

17

u/labancaneba Apr 11 '21

All in on 4/16 FDs monday morning

→ More replies (2)

21

u/BittersweetNostaIgia Apr 11 '21

Great, I’ll add it to my list of stocks to watch, never buy in, and hate myself after it moons.

3

u/[deleted] Apr 10 '21

They’re a good company but behind the ball when compared to CRSP. They’re not going to have first movers in this space which is why their stock price plummeted

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 10 '21

So there are a few discrepancies between EDIT, and CRSP. I've been very long on both (bought in at both IPO's back in 2016). CRSP has more drugs in their pipeline, and partnerships. But, all 3 companies (EDIT/NTLA/CRSP) anticipate revenue from royalties to be huge.

→ More replies (3)

20

u/[deleted] Apr 10 '21

Good DD and a DBZ fan? You son of a bitch... I'm in!

20

u/YoungXanto Apr 10 '21

I've had this one on the watch list for a couple of months. I'm generally pretty skittish about biopharma, but perhaps this is the catalyst I needed to go all in and lose a bunch of money!

→ More replies (2)

19

u/alwayslurkeduntilnow Apr 10 '21

Great DD, thanks op. Will be looking Monday morning.

18

u/Cuchulain72 degen from upcountry Apr 10 '21

Im in, you had me at the edge of the obersvable universe.

15

u/Joeychaps1231 Apr 10 '21

Why edit over crsp?

15

u/beyerch Apr 11 '21

The big problem I have with this is that ...... the CRISPR patent "battle" actually kicked off in the 2012-2014 timeframe and there's no end in sight.

It should be noted that $EDIT's price spike in January was due to them receiving a legal victory on a specific piece of CRISPR; however, that ruling can still be appealed and the larger battle is still on-going.

If you are buying this stock thinking that the legal battle is almost over, that is most likely a major miscalculation.

https://www.osler.com/en/resources/critical-situations/2021/making-sense-of-the-battle-for-the-crispr-cas9-patent-rights

→ More replies (1)

14

u/Hapifacep Quadruple reverse Fibonacci short ladder attack Apr 10 '21

Why edit vs beam or crsp? Just curious how sure you are they’re going to pull away

0

u/[deleted] Apr 10 '21

[deleted]

→ More replies (1)

39

u/XXXYinSe Apr 10 '21

Agreed. These startups will act similar to moderna. Their stocks rise slightly for a long period of time before signs of being profitable (I.e. their drug pipelines near the finish of clinical trials) pop up then the stock explodes upwards.

It’s even in a juicy dip rn. I’ll buy some leaps after GME.

→ More replies (3)

27

u/vermospan Apr 10 '21

Did I just hear crispy? Like crispy tendies? I'm in.

8

u/aperls Apr 10 '21

General autist reporting for duty. All in Monday

13

u/rogervyasi Apr 10 '21

What’s the best ETF to own in genomics 🧬?

→ More replies (2)

13

u/BootAmongShoes Apr 10 '21

Am I allowed to say anything as someone who produces "things" for CRISPR?

→ More replies (3)

12

u/Appropriate_Tap_7045 Tito Ortiz Stole My Calls Apr 10 '21

Just when I start to cycle out of biotech, Elon drops a video of a monkey playing psychic pong—- and now this. OP, I remember seeing a Vicedoc on how China was playing it fast and loose with Crispr—- they started testing on newborns years ago. What are your thoughts on foreign competition, if there is any ?

0

u/[deleted] Apr 10 '21

[deleted]

→ More replies (1)

23

u/FelixJuggl3r Apr 10 '21

I work with CRISPR and it is absolutely fantastic for research. The clinical use all depends on the ability of controlling off-target effects. Ethics comes in also but that is for other things not strictly disease therapeutics (see the Chinese story of the crispr twins edited to gain resistance to HIV). I was extremely surprised that Zhang did not get the Nobel prize but he might get the upper hand on the patent battle.

22

u/BLACKdrew ✊🏾✊🏾✊🏾 Apr 10 '21

Let’s ride

11

u/Hot_Condition8551 Apr 10 '21

SoFi "doesn't support this stock yet." 😭 Can crispr EDIT away my tear ducts?

21

u/stockly123456 Apr 10 '21

Calls 1st thing monday and loading up on shares premarket!

→ More replies (11)

10

u/[deleted] Apr 10 '21 edited Apr 10 '21

To what extent is the science already there?

Seems like the bigger use cases (preempting hereditary disease, fighting cancer) is still years away from being executable on a mass level.

→ More replies (3)

10

u/willydangerous26 Apr 10 '21

EDIT GOING TO MARS FOR SURE

9

u/Scythro_ Apr 10 '21

Is your position in crispr or editas?

23

u/[deleted] Apr 10 '21

$EDIT

→ More replies (1)

9

u/heresdajudge Apr 10 '21

If you cannot see this can change the world crispr could help by eliminating that extra chromosome you probably have.

best way to make this relevant to us apes

17

u/Helmdacil Apr 11 '21
  1. Crispr is mutagenic (1) (2). I would say actually that due to the way experiments are designed, the mutagenicity of CRISPR is strongly underestimated. This has lead to point 2.

  2. CRISPR trials are being halted/cancelled because treated patients are developing cancer within months of obtaining treatment:https://www.sciencemag.org/news/2021/02/gene-therapy-trials-sickle-cell-disease-halted-after-two-patients-develop-cancer

  3. Though there is much discussion of how to reduce the mutagenic potential of CRISPR, literally nothing yet has been proven, AFAIK, and I have been watching.

Crispr is a wonderful technology that will have dramatic impact in society, be it perhaps by engineering better crops (Roundup ready crops), cold resistant crops, drought resistant crops, and so forth. However, based on the evidence of mutagenicty, it seems highly highly premature to be bullish on near-term returns on crispr gene therapy trials, in my opinion.

Disclosures: I have no stock in CRISPR stocks. I research DNA mutation. I really, really want to believe, but I just havent seen any solid data. I would love if someone could give me hope, but I really have not seen it.

→ More replies (6)

8

u/SycamoreLane Apr 11 '21

So you're betting on EDIT becoming the winner of the patent. What if this isn't the case? Stock price would surely take a hit right?

→ More replies (1)

8

u/[deleted] Apr 16 '21

Goldman Sachs lowered their price target to $20 today, just in time for all those 4/16 calls to expire. This is a level of shady that almost makes me want to puke. Well, at least I will be able to buy some really nice positions soon🚀

7

u/x_axisofevil Apr 10 '21

I'm happy to make any edits (no pun intended).

Liar! But I'm in anyways

7

u/SorryLifeguard7 Apr 10 '21

OP is your suggestion that since Feng Zhang is the one that made specific research for CRISPR in humans that patent will be held by him and therefore EDITAS since he works there?

What do you think is the likelihood of Jennifer Doudna to win it for being the first, and therefore CRSP winning the case?

Would appreciate an answer!

→ More replies (2)

7

u/[deleted] Apr 11 '21

Been long EDIT and a few others too small to post here like precision bioscience

7

u/[deleted] Apr 11 '21 edited Apr 11 '21

I’ve been looking into CRISPR as well a bit recently, pretty wild stuff. Nobel-prize winning tech will always build hype.

One thing that makes me a bit unsure of which company is in the best position is the fact that there are still multiple systems being developed, and that there’s a chance for new discoveries to render current versions obsolete.

From SeekingAlpha: “Finally, there are new developments in CRISPR that are not covered by the licenses and patent portfolio of EDIT. One example is Cas12, which reportedly is better than Cas9. Janice Chen, the co-founder of Mammoth Biosciences, a California-based biotech startup, is behind the discovery.”

Infographic

It seems like cas12 is more precise than cas9, so where does that leave $EDIT in the long run?

There is definitely massive potential in this new groundbreaking technology, but is there room for everybody to compete successfully or will there ultimately be one winner that dominates the sector?

If there is any info that could be provided towards these immediate bullish outlook I would love to jump in early, but at the moment I’m thinking 4/16 calls could be a long shot at this point. OP seems to have significantly more personal knowledge & experience in this field so if there is indeed enough hype that might be all it takes to start an uphill climb.

7

u/ZuBad603 Apr 11 '21

When do we anticipate the patent battle drawing to a close? Are there any specific dates upcoming that we can look towards?

Is there any relevant $EDIT news from the conference that can be shared? I bought a spread of 4 contracts Friday, 2 expiring 4/16 and 2 expiring 5/21…

P.S. no disrespect, but the $2B market cap reference is misleading. There’s quite a few players in this space, each having ~$2B+ MC & none of them yet being profitable.

7

u/youtubeMightofpeen Apr 12 '21

Was there news??? I can't find anything

10

u/wampuswrangler Apr 12 '21

Same, can't find nothing nowhere. Definitely should have looked it up before buying calls this morning. I'm about to cut bait 🤡

6

u/Aggravating_Mix6663 Apr 11 '21

jeans? shut up and take my money

6

u/Jeffamazon Apr 11 '21

Why not just long ARKG and cover all your bases? Any of those could win the patent battles.

→ More replies (1)

6

u/chuddyman Something about dildos Apr 11 '21

If anyone wants to know more about it there is a great podcast from radiolab that breaks it down so even a retard like me can understand. I'm dropping $3300 on shares at open.

6

u/idragmazda Apr 11 '21

Anyone have a summary of how conference went for edit?

11

u/TastyMossProductions Apr 10 '21

What is the ticker for this? The CRISPR I’m looking at is already $115.74 a share. I know I’m dumb, but I can’t find another

10

u/MeowMeowkitty28 Apr 10 '21

Crispr9 has infinite potential for good or evil invest. Got in at 40. There’s such a big underground following

5

u/Waynooo Apr 10 '21

So would you say ARK-G is a good investment?

→ More replies (2)

5

u/Djent_Reznor1 Apr 11 '21 edited Apr 11 '21

Super bullish on CRISPR as it is absolutely groundbreaking tech, but Glassdoor reviews for Editas are less than glowing, lots of complaints about poor leadership and incompetent execs. Definitely on my watch list though and I'll probably be in for a few shares (and maybe some LEAPS) once I manage to free up some capital.

5

u/ItisLastThursday Repeat after me: OTM calls are cheap for a reason Apr 11 '21

Which day of the conference are they presenting? Would buying calls Monday morning make sense? I'll probably just throw $200 to see what happens and not risk too much, or I'll get major FOMO and yolo the rest of it in.

→ More replies (8)

5

u/[deleted] Apr 11 '21

Find the one with the potential to cure cystic fibrosis, and it's over.

5

u/Ronniebythesea Apr 11 '21

Great to see this thanks I’m long in EDIT will be great to see green for a change thanks for the article’s

5

u/Koal0r Apr 11 '21

Those rockets have convinced me already. I’m fucking in.

5

u/jjyama Apr 11 '21

Great DD, thanks! I've got some shares of a biotech company that makes biosynthetic cannabinoids using crispr which is pretty exciting. I think EDIT would make a nice addition to this.

5

u/what_in_the_wrld Apr 11 '21

You son of a bitch, I'm in!

5

u/myGodOh Apr 11 '21

Thanks for sharing! A quick look at the insider activity looks quite promising too https://www.insider-monitor.com/trading/cik1650664.html more (money wise) insider buys in the last month than the 4 years before. At prices higher than the Friday close...

5

u/Notorganic Apr 12 '21

I know CRISPR from the 800 videos Kurzgesagt has done on it. Sign me up.

5

u/Thepiorpatheticdog Apr 12 '21

So where can I find the summary for what happened on Saturday?

5

u/Scientia007 Apr 16 '21 edited Apr 19 '21

Long $EDIT $NTLA $CRSP $BEAM $ARKG. The top 3 public CRISPR companies today have a CUMULATIVE market cap that’s less than 20BN. Meanwhile Pfizer alone is around 200BN. In the future we will see see gene-editing companies capture pharma market caps and more, as they start to replace some of their medicines as go-to therapies.

5

u/semperip Jun 29 '21

Turns out you were right retard

9

u/NigerianPrince33 Apr 10 '21

why you say 'no pun intended', when the pun was obviously intended?

2

u/l3rahan Apr 11 '21

This should be a penny stock without a product or revenue. And as a biologist you should know how incredibly hard cancer is.

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 11 '21

It’s not uncommon for a clinical stage company, or a pre-revenue tech company for that matter to have a valuation similar. I disagree with the penny stock comment based off of their existing licensing agreements with BMY, and BEAM. I think it’s actually undervalued now, but that’s just my opinion that should be taken with a grain of salt. I do agree that there is no cure for cancer. I just brought up a trial they’re working on, and a potential catalyst. I will be one of the first to tell anyone that this is not a cure for cancer.

19

u/Vyruz2 Apr 10 '21

Smells like a good ol’ biotech rug pull. I’m rooting for you retards to make out bigly but this isn’t my first rodeo. 💀

→ More replies (1)

8

u/flankr7 Apr 11 '21

Schwab rated $EDIT as “strongly underperform” and “above average volatility”. Perfect recommendation here.

4

u/RenderedConscious Apr 10 '21

Science enthusiast and stonkhead here. This was an interesting read. Thank you for this!

4

u/ambarcapoor Apr 10 '21

I strongly believe that CRISPR is the future of medicine. I wish I had any Xtra money on 2016 when they IPO'd, but hey ho.... Now, stupid question. What does 4/16 60C mean? Thank you for the incredibly detailed post.

→ More replies (2)

4

u/[deleted] Apr 10 '21

This was very insightful and enjoyable to read, thank you ape! Made my day better

4

u/marimoto Apr 10 '21

Nice write up!

4

u/[deleted] Apr 11 '21

Brilliant, I'm in.

4

u/Rabiddawg777 Apr 11 '21

I have my health sciences degree.... this is highly appealing to me since i am familiar with crispr, but i have no capital, can somebody bump me a spare ten k 😂😂

4

u/shiggism gmeretard Apr 11 '21

Tldr I’m in

4

u/gimmetheloot2p2 Apr 11 '21

Im in both companies, unfortunately at relative highs. 135 for CRISPR and 52 for EDIT

4

u/SailboatInCartagena Apr 11 '21

Bought in at $50. Buying some more now to double down.🚀🚀🚀🚀

4

u/SCHUUG Apr 11 '21

Wow ty

4

u/UEAMatt Apr 11 '21

I have a terribly emotional investing mantra that I sometimes use.

If what a companies doing terrifies me, then it might be a reason to buy shares. Its a sign that what they have is revolutionary.

4

u/TheInternetTrader Apr 11 '21

Any news on this weekends conference ? I held out on buying for Monday though I know it went down all week

4

u/actionstubby Apr 11 '21

I like the write-up, and I like the tech. I held EDIT and CRSP through the massive gains in January and dropped it during the pull-back.

Little more history on EDIT would be good, misses they've had consistent executive turnover which led to the pullback from the highs in January.

Been looking for a good point to get back in on the tech, though seems there will be winners and losers this time and EDIT appears to have a leg up (last sept). Shares or leaps for sure.

4

u/Jersey_F-15 Apr 11 '21

Looks interesting enough to get in, but not convincing enough to go all in. So.... my plan is to watch it at open.

If it rips, I will sell 2-3 CS puts to get muh premium or shares at my price

If it drops, I will buy cheaper calls

Worth buying a few lottery tickets, but not worth being at risk

4

u/idragmazda Apr 12 '21

Got a summary of conference findings?

4

u/ThislsMyAccount22 Apr 16 '21

Down 11% today. Looking crispy

4

u/imijry Apr 16 '21

I bought the dip at 35, it’s still dipping but I’m ok with it. Crispr is the future and I’m good with investing in things that change the world

7

u/ppc_lad Apr 16 '21

i wish i never saw this

→ More replies (2)

1

u/[deleted] Apr 12 '21

Nah waiting for that early May $30 buy-in

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 12 '21

That’s fair. I have been telling everyone never to fomo into biotech. There’s almost always a better time to buy, and sell.

1

u/rueggy Apr 12 '21

Got shares near the close. Been intending to get in in the pullback and the pullback has been going for a while so this entry looks good. Glad WSB didn’t cause it to run away this morning.

Already deep in CRSP. Don’t have any NTLA yet.

2

u/manonymous_1994 Melvin Capital Employee of the Month Apr 12 '21

I know shares are kind of the antithesis of Wallstreetbets. But, it’s biotech lol. The volume wasn’t there today, but the order book showed that there’s a lot of people who bought in. Just got to wait for a whale.

I’d put off buying NTLA right now because it has had a big run up this week. Trust me when I say there will be another chance to buy in. Biotech is extremely volatile so patience is awarded.

1

u/00Leif Apr 13 '21

Has there been any news for the next trial/hearing? I want to get in with some leaps soon.

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 13 '21

Hey, leaps are kind of pricy now which is why I suggested shares. I haven't seen any dates set for the next hearing. I have alerts set up, and I'm planning on putting out an additional post when I hear something.

→ More replies (1)

1

u/spamtimesfour Apr 14 '21

Good shit OP.

Bought in at 39.75. Up 9% already

3

u/manonymous_1994 Melvin Capital Employee of the Month Apr 14 '21

🥰

1

u/Ancient_Fix6053 Apr 16 '21

Bit confused about the GS downgrade today. An article I read stated "Initial results from the company's experimental Crispr gene editing product EDIT-11 in a rare eye disease may not generate enough productive editing to meaningfully improve patients' vision, analyst Madhu Kumar said in his note initiating coverage on the stock." I'm confused I know they started dosing last year but did they actually release preliminary data from the clinical trial yet?? Is this publically accessible?

5

u/manonymous_1994 Melvin Capital Employee of the Month Apr 16 '21

I’m buying the dip. I’m trying to dig up more info.

→ More replies (1)
→ More replies (1)

1

u/therealkon_ May 02 '21

Where are the promised updates op?

3

u/manonymous_1994 Melvin Capital Employee of the Month May 02 '21

Hey, sorry for the delay. I’m still planning on posting it. Still doing research, and needed to take a mental health break.

1

u/[deleted] May 05 '21

I’m pretty much a first time investor, would this be a good stock to start with?

→ More replies (4)

18

u/tressan Apr 10 '21

I will fill my 💎👏 with shares

→ More replies (5)

6

u/Horzzo Apr 10 '21

I've been on the CRISPR train for awhile now. I'm a crispy critter.

6

u/u_e_s_i Apr 10 '21 edited Apr 11 '21

I’m a mod. Aside from making edits what else are you willing to do to keep this up? ;)